KGbio
Edric Hernando has experience in business development and licensing at KGbio, where they finalized partnership agreements worth USD 15 Mio for out-licensing novel biologics products. They also played a pivotal role in creating company branding and marketing materials. Prior to this, Edric served as an Official Campus Ambassador at International MUN, contributing to the social media promotion of the conference and increasing participation. Their experience as a Laboratory Assistant at Universiti Putra Malaysia involved conducting nanomaterial synthesis and various assays. Edric holds a Bachelor's degree in Biomedical/Medical Engineering from Universitas Airlangga.
KGbio
KGbio is a clinical-stage biotechnology company focused on bringing biologics medical innovation to markets outside the US/Canada, Western Europe and China. The business model revolves around in-licensing novel biologics and select biosimilars in oncology and high-specialty therapeutic areas (typically pre-IND or early clinical stage), with the objective to out-license them in target geographies after finishing clinical development as well as regulatory and reimbursement approvals. Platforms of interest currently include Fc-fusion proteins, antibodies, bispecifics, ADCs, cell therapies and therapeutic vaccines. The company is backed by Asian pharma companies Kalbe (market cap US$5.5 billion) and Genexine (market cap US$1.3 billion) and US private equity giant General Atlantic (AUM US$ 78 billion).